CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists
CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors...
Read MoreCatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and...
Read MoreCatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers
CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition...
Read MoreCatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination...
Read MoreCatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation
CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy...
Read MoreCatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance
CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor...
Read MoreCatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023
CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody...
Read MoreCatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting
CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab...
Read MoreCatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort
CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in...
Read MoreCatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate...
Read More